Niveau de preuve du suivi thérapeutique pharmacologique des aminosides
- PMID: 27393463
- DOI: 10.2515/therapie/2011001
Niveau de preuve du suivi thérapeutique pharmacologique des aminosides
Abstract
Aminoglycosides are major antibiotics indicated for the treatment of infection with gram-negative bacilli. They are characterized by high clinical effectiveness but their main drawback is the occurrence of toxicity in a significant number of patients. Pharmacokinetic parameters of aminoglycosides exhibit wide inter-individual variability and the relationships between concentration and effect have been clearly demonstrated. Consistent studies have demonstrated that therapeutic drug monitoring (TDM) of aminoglycosides administered in multiple daily doses was cost-effective in maximising antibiotic efficacy and/or reducing incidence of toxicity. Therefore TDM of aminoglycosides should be considered "essential". Level of evidence for TDM of aminoglycosides administered once daily is not so clearly demonstrated however it should be highly recommended.
Keywords: aminoglycosides; aminosides; pharmacocinétique; pharmacodynamics; pharmacodynamie; pharmacokinetics; suivi thérapeutique pharmacologique; therapeutic drug monitoring.
Copyright © 2011 Société Française de Pharmacologie et de Thérapeutique. Publié par Elsevier Masson SAS.
Publication types
LinkOut - more resources
Full Text Sources